WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC 5th levels

List of latest ATC/DDD decisions from the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the decisions should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline (see list). If no objections are received, the new ATC/DDD decisions will be considered final and included in the ATC/DDD Index. In the list final indicates that the date for objection has expired. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the ATC and DDD alterations are only valid and implemented in the coming annual updates of January 1st.

ATC codeATC level nameDeadline for objection to temporary codesImplementation in ATC/DDD index
A05AA06norucholic acid01.02.20252026
A05AX08linerixibat01.02.20252026
A05BA11resmetirom01.02.20252026
A10AE57insulin icodec and semaglutide01.02.20252026
A10BD31metformin, sitagliptin and dapagliflozin01.02.20252026
A10BD32glimepiride and dapagliflozin01.02.20252026
A10BD33pioglitazone and dapagliflozin01.02.20252026
A12CB04zinc orotate01.02.20252026
A16AB28verenafusp alfa01.02.20252026
A16AX26glepaglutide01.02.20252026
A16AX27apraglutide01.02.20252026
A16AX28sepiapterin01.02.20252026
A16AX29doxecitine and doxribtimine01.02.20252026
B02BD18arvenacogene sanparvovec01.02.20252026
B02BX12fitusiran01.02.20252026
B06AC09donidalorsen01.02.20252026
B06AX06lovotibeglogene autotemcel01.02.20252026
B06AX07mozafancogene autotemcel01.02.20252026
C03EB03torasemide and potassium-sparing agents01.02.20252026
C09BB14zofenopril and amlodipine01.02.20252026
C10BA14pitavastatin and fenofibrate01.02.20252026
C10BX23rosuvastatin, amlodipine and ramipril01.02.20252026
C10BX24rosuvastatin, amlodipine and telmisartan01.02.20252026
D03AX17diperoxochloric acid01.02.20252026
D06BB13berdazimer sodium01.02.20252026
D11AA02sofpironium bromide01.02.20252026
G02CX07elinzanetant01.02.20252026
J01FA17nafithromycin01.02.20252026
J07BB55influenza and covid-19, RNA-based vaccine01.02.20252026
J07BX07chikungunya vaccines01.02.20252026
L01EB12firmonertinib01.02.20252026
L01EC04tovorafenib01.02.20252026
L01EE06tunlametinib01.02.20252026
L01EH04zongertinib01.02.20252026
L01EK05rivoceranib01.02.20252026
L01EP03 savolitinib 01.02.20252026
L01EX29vimseltinib01.02.20252026
L01FF14camrelizumab01.02.20252026
L01FF15envafolimab01.02.20252026
L01FX37linvoseltamab01.02.20252026
L03AC03nogapendekin alfa and inbakicept01.02.20252026
L04AA61nerandomilast01.02.20252026
L04AC27cendakimab01.02.20252026
L04AF09deuruxolitinib01.02.20252026
L04AG18sibeprenlimab01.02.20252026
L04AG19axatilimab01.02.20252026
L04AL03nipocalimab01.02.20252026
N06BX53piracetam and cinnarizine01.02.20252026
N06DA06benzgalantamine01.02.20252026
N06DX06blarcamesine01.02.20252026
N06DX07hydromethylthionine01.02.20252026
N07XX26pridopidine01.02.20252026
P02CA53albendazole and ivermectin01.02.20252026
R03BX02ensifentrine01.02.20252026
R03DX12depemokimab01.02.20252026
S01BA17clobetasol01.02.20252026
V04CX13pegulicianine01.02.20252026
V09IX19vidoflufolastat (18F)01.02.20252026

Last updated: 2024-12-11